FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.